RxDoctor Payments Data

Jacquelyn White, MD

Emergency Medicine · Ruston, LANPI 1629186812

Payments from drug & device makers

$479in general payments, 2019–2025

Across 15 payments — averaging $31.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BD$149
  • Novo Nordisk$125
  • Gilead$41
  • AstraZeneca$40
  • Exact Sciences$37
  • Lilly USA, LLC$35
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
BD1$149
Novo Nordisk1$125
Gilead3$41
AstraZeneca3$40
Exact Sciences2$37
Lilly USA, LLC2$35
Bayer1$24
AbbVie1$17
Merck1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479 in reported general payments places this provider in the 85th percentile of 881 emergency medicine providers in Louisiana.

See all emergency medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,946
Medicare patients
25
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol21$12,297
Tiagabine Hcl19$11,544
MyrbetriqMirabegron20$9,687
JanuviaSitagliptin Phosphate15$9,136
JanumetSitagliptin Phos/Metformin Hcl16$8,466
JardianceEmpagliflozin13$8,152
Potassium Chloride140$7,227
Paliperidone ErPaliperidone14$6,191
Divalproex Sodium ErDivalproex Sodium41$5,298
Quetiapine Fumarate ErQuetiapine Fumarate12$4,377
Alendronate Sodium66$3,875
Tacrolimus13$2,099
Oxybutynin Chloride ErOxybutynin Chloride28$1,486
Methenamine Hippurate12$1,177
Mycophenolate Mofetil11$1,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$11$17,60231 claims
AstraZenecaFarxiga$40$12,29721 claims
Lilly USA, LLCOlanzapine$35$43824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 881 emergency medicine providers in Louisiana.

Other emergency medicine in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →